NCT04547205View on ClinicalTrials.gov

A Study of Anti-VEGFR2 AK109 in Subjects With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 6, 2020

Primary Completion Date

March 24, 2021

Study Completion Date

October 31, 2022

Conditions
Solid Tumor
Interventions
DRUG

AK109

AK109, 2#4#8#12#18mg/kg, IV, every 2 weeks (Q2W), or 15 mg/kg every 3 weeks(Q3W)

Trial Locations (1)

310009

The First Affiliated Hospital of Medicine College, Zhejiang University, Hangzhou

Sponsors

Lead Sponsor

Akeso
All Listed Sponsors
lead

Akeso

INDUSTRY

NCT04547205 - A Study of Anti-VEGFR2 AK109 in Subjects With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter